Green Cross first NDA approval for anticancer drug from US FDA
Published: 2009-07-13 06:56:00
Updated: 2009-07-13 06:56:00
Green Cross Corporation said on July 7 it received the first new drug approval (NDA) from US Food and Drug Administation for greenstatin, an investigational anticancer drug that inhibits the formation of new blood vessels in tumors.
Company officials said that greenstatin, co-developed between...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
